BLOOMBERG Bloomberg Markets Americas July 11, 2024
With its trial. There were two trial participants. One had efficacy of 90 . The other was lower than that, in the 60s. You average that, and it its about 70 . We will see how the market is moving on that. We want to welcome now to our bloomberg tv and radio on a sense Radio Audience astrazenecas executive vice president. It is really good to see you. When itways welcome, comes to good news over solid vaccines. The question it seems people want insert is talk about that 90 efficacy. That seems to have been a smaller group. Give me some insight into it. How many confirmed cases were there in tha...